The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Primary analysis of the EORTC-2139-MG/Columbus-AD trial: A randomized trial of adjuvant encorafenib and binimetinib versus placebo in high-risk stage II melanoma with a BRAF-V600E/K mutation.
 
Alexander van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Genmab; Menarini Silicon Biosystems; Merck/Pfizer (Inst); MSD Oncology (Inst); NeraCare GmbH; Novartis (Inst); Pierre Fabre (Inst); Provectus Biopharmaceuticals; Sanofi (Inst); Sirius Medical (Inst); Skyline Diagnostics
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis
 
Mario Mandala
Honoraria - Bristol-Myers Squibb/Sanofi; LEO Pharma; MSD Oncology; Novartis; Pierre Fabre; Regeneron; Sanofi/Aventis
Consulting or Advisory Role - Bristol-Myers Squibb; LEO Pharma; MSD Oncology; Novartis; Pierre Fabre; Regeneron
Research Funding - Novartis (Inst)
 
Michal Kicinski
Research Funding - BMS (Inst); Immunocore (Inst); Janssen (Inst); Merck (Inst); Pierre Fabre (Inst)
 
Anne-sophie Govaerts
No Relationships to Disclose
 
Axel Hauschild
Honoraria - Agenus; Almirall Hermal GmbH; Bristol-Myers Squibb; CureVac; Immunocore; Incyte; IO Biotech; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Philogen; Pierre Fabre; Regeneron; Replimune; Roche; Sanofi/Aventis; Skyline Diagnostics; Sun Pharma; Xenthera
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Immunocore; IO Biotech; Merck Serono; Merck Sharp & Dohme; Novartis; Philogen; Regeneron; Replimune; Roche; Sanofi/Aventis
Research Funding - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Regeneron; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche; Sanofi/Aventis
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Genesis Pharma; Medison; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Philogen; Pierre Fabre
Speakers' Bureau - Novartis; Pfizer; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre
 
Petr Arenberger
Honoraria - Abbvie; Bristol-Myers Squibb/Pfizer; Janssen; La Roche-Posay; Merck; Novartis; Pierre Fabre; Sanofi/Aventis
Consulting or Advisory Role - Abbvie; Sanofi/Aventis
Research Funding - Pfizer
 
Paolo Ascierto
Consulting or Advisory Role - Anaveon; Bayer; Bio-AI Health; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Erasca, Inc; Genmab; Immunocore; Italfarmaco; Lunaphore Technologies; Medicenna; Menarini Silicon Biosystems; Merck Sharp & Dohme; Nouscom; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi; Sun Pharma; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Philogen; Pierre Fabre; Replimune
 
Piotr Tomczak
No Relationships to Disclose
 
Gaelle Quereux
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre
Travel, Accommodations, Expenses - Pierre Fabre
 
Federica De Galitiis
No Relationships to Disclose
 
Caroline Dutriaux
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Regeneron; Sun Pharma
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Regeneron; Sun Pharma
 
Christoffer Gebhardt
Stock and Other Ownership Interests - Dermagnostix
Honoraria - Bristol-Myers Squibb; Delcath Systems; Immunocore; Medscape; MSD; Novartis; Onkowissen; Pierre Fabre; Regeneron; Sanofi; Sun Pharma
Consulting or Advisory Role - BioNTech; Bristol-Myers Squibb; Delcath Systems; Immatics; Immunocore; Iovance Biotherapeutics; MSD; Novartis; Pierre Fabre; Regeneron; Sanofi; Skyline Diagnostics
Speakers' Bureau - Bristol-Myers Squibb; Delcath Systems; Immunocore; MSD; Novartis; Pierre Fabre; Sun Pharma
Research Funding - Bristol-Myers Squibb; Novartis; Pierre Fabre; Regeneron; Sanofi
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre; Sun Pharma
 
Ellen Kapiteijn
Consulting or Advisory Role - Delcath Systems (Inst); Immunocore (Inst); Lilly (Inst)
Research Funding - BMS (Inst); Delcath Systems (Inst); Novartis (Inst); Pierre Fabre (Inst)
 
Laurent Machet
No Relationships to Disclose
 
Isabelle Klauck
Employment - Pierre Fabre
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Pierre Fabre
 
Benoit Sansas
Employment - Pierre Fabre
 
Paul Lorigan
Stock and Other Ownership Interests - Supportive Care; The Christie Private Care
Honoraria - BMS; Iovance Biotherapeutics; MLA Dx
Consulting or Advisory Role - Bristol-Myers Squibb; Iovance Biotherapeutics; Merck Sharp & Dohme; NeraCare GmbH
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - BMS (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Georgina Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; GI Innovation Inc; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron; Scancell LImited; Skyline Diagnostics
 
Alexander Eggermont
Stock and Other Ownership Interests - IO Biotech; Sairopa; Skyline Diagnostics
Honoraria - Agenus; Bioinvent; BioNTech; Boehringer Ingelheim; Brenus Pharma; Catalym; Ellipses Pharma; Genoway; GlaxoSmithKline; IO Biotech; IQVIA; ISA Pharmaceuticals; Merck; MSD; Pfizer; Pierre Fabre; Sairopa; Scorpion Therapeutics; Sellas Life Sciences; Skyline Diagnostics; TigaTx; Trained Therapeutix Discovery
Consulting or Advisory Role - Agenus; Bioinvent; BioNTech; Brenus Pharma; Catalym; Ellipses Pharma; Genoway; GlaxoSmithKline; IO Biotech; IQVIA; ISA Pharmaceuticals; Merck; MSD; Pfizer; Pierre Fabre; Sairopa; Scorpion Therapeutics; Sellas Life Sciences; Skyline Diagnostics; TigaTx; Trained Therapeutix Discovery
Speakers' Bureau - Bristol-Myers Squibb; Merck; MSD